Toll-like receptor 3 (TLR3) often designated as CD283 (cluster of differentiation 283) is a type I transmembrane receptor protein. It belongs to a family of evolutionary conserved innate immune recognition molecules and recognizes double-stranded RNA, a molecular pattern associated with viral infections. Like all other members of the TLR family, TLR3 is composed of an extracellular domain containing multiple leucine-rich repeats (LRRs), a transmembrane region, and a cytoplasmic tail containing the conserved TIR domain. The transmembrane domain consists of a single alpha-helix spanning the membrane, while the TIR domain is made up of a five-stranded beta-sheet surrounded by five alpha-helices. The human TLR3 ectodomain structure at 2.1 angstroms reveals a large horseshoe-shaped solenoid assembled from 23 LRRs (1). The TLR3 gene maps to chromosome 4q35 and its sequence encodes a putative 904 amino acid protein and a calculated molecular weight of 97 kDa. TLR3 is most closely related to TLR5, TLR7, and TLR8, each with 26% overall amino acid sequence identity. In vivo, two different sized transcripts for TLR3 are observed suggesting that the mRNA is alternatively spliced to generate two different forms of the protein.
in response to pathogen recognition. Trif contains a RIP homotypic interaction motif (RHIM) at the C terminus that is essential for binding of RIP1 and RIP3, two serine-threonine kinases linked to tumor necrosis factor (TNF)−mediated NF-
B activation. (3, 4, 5). Activation of TLR3 leads to recruitment of receptor-interacting protein 1, TRAF3 and TRAF6, which activates TRAF family member-associated NF-
B activator-binding kinase 1 (TBK1) andr inducible I
B kinase (IKK-i), which directly phosphorylate IRF3 and IRF7 for the production of type-I IFN cytokines.(6)
Reference:
1. J Endotoxin Res. 2006; 12(6):375-8
2. Nature. 2001 Oct 18; 413(6857):732-8
3. Nature Immunology 5, 503 - 507 (2004)
4.Rock, F.L. et al. (1998) Proc. Natl. Acad. Sci.
5. Science. 2005 Jul 22; 309(5734):581-5. Epub 2005 Jun 16
6.Oncogene (2008) 27, 181–189; doi:10.1038/sj.onc.1210906
7. Clinical Microbiology Reviews, January 2008, p. 13-25, Vol. 21, No. 1
Article Source:http://www.articles321.com
|